At constant currencies, Astra’s revenue grew 7% year on year, and core EPS rose 19%. Management reiterated its guidance and announced a three-year restructuring program to reallocate $1.5 billion of annual costs to its pipeline. Shares closed 7% higher on Oct. 30, from the previous day’s close.
The company has a healthy oncology portfolio, including Tagrisso, Imfinzi, Calquence, Enhertu, and Truqap, which looks well positioned to drive major cash flows over the next decade.
The company's strong entrenchment in respiratory disease could cause challenges, as pricing power in this market tends to be weak.
|
Metric
|
AZN
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 17.26 | 16.24 | 119.22 |
Price/Book Value | 5.51 | 8.08 | 8.52 |
Price/Sales | 4.60 | 5.33 | 5.31 |
Price/Cash Flow | 17.77 | 15.65 | 16.20 |
|
Metric
|
AZN
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.79 | 0.58 | 0.71 |
Current Ratio | 1.01 | 0.88 | 1.32 |
Interest Coverage | 8.25 | 8.78 | 4.28 |
|
Metric
|
AZN
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 9.32% | 14.70% | 6.27% |
Return on Equity (Normalized) | 22.09% | 40.76% | 16.68% |
Return on Invested Capital (Normalized) | 14.75% | 21.22% | 9.74% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|$qYFvx^B | LOCK|zr | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|H$g!!%k | LOCK|Kf! | $641B | |||
| AbbVie Inc
ABBV
| LOCK|T$!&Wh^ | LOCK|ZY& | $506B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|?^Qyg%h | LOCK|Lwd | $382B | |||
| Merck & Co Inc
MRK
| LOCK|!$WL&hm | LOCK|^XZ | $357B | |||
| Novartis AG ADR
NVS
| LOCK|^Gdc>%sv | LOCK|<YC | $303B | |||
| Amgen Inc
AMGN
| LOCK|^g<!p$$ | LOCK|$! | $249B | |||
| Gilead Sciences Inc
GILD
| LOCK|TPJq#n | LOCK|ZF% | $208B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|<&?f$j< | LOCK|jN | $178B |
United States